Nishakatakadi Ghan Vati with Kanchnaar Guggulu versus Panchtikta Ghrita Guggulu with Shigru Patra Ghan Vati after Virechana in Prameha (Type 2 Diabetes Mellitus)

A Comparative Study of Nishakatakadi Ghan Vati with Kanchnaar Guggulu versus Panchtikta Ghrita Guggulu with Shigru Patra Ghan Vati preceded by Virechana in Prameha (Type 2 Diabetes Mellitus): Randomized Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099439

Enrollment

Registered

2025-12-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.With classical signs of Prahmeha (~ Type 2 Diabetes Mellitus-The specific TM2 Code for Prameha is AK85. 2.Diabetic profile: RBS 200 350 mg/dl, FBS 126 250 mg/dl, PPBS 200 350 mg/dl, HbA1c 6.5 10 3.Thyroid profile: TSH less than 4.5- 10 IU/ml, T3 greater than 80 220 ng/dl, T4 greater than 4.5 12.5 g/dl 4.Patients fit for Snehpana and Virechana Karma 5.Willing to participate in trial NOTE (In the above-given criteria, there is one should be present and raised HbA1C and TSH is necessary.) Newly /early diagnosed cases to be included as per following criteria: 6.Patients who are taking any conventional medicine for Type 2 Diabetes mellitus and hypothyroidism whose sugar level and TSH levels are raised and fall within the inclusive criteria mentioned above and are willing to take Ayurvedic treatment. 7.Diagnosed patients (Maximum 5 years of diabetic history and hypothyroidism history)

Exclusion criteria

Exclusion criteria: 1.Patient having insulin dependent DM (type 1) OR receiving insulin 2.Excessive blood glucose: FBS greater than 250 mg/dl, PPBS greater than 350 mg/dl, RBS greater than 350 mg/dl and HbA1c greater than 12 3.Emergency conditions in cases of DM. 4.Chronic complications like microvascular and macrovascular derangements. 5.Patients reporting to be hypersensitive to any of the proposed trial drugs. 6.Pregnant women/ lactating mothers 7.Participation in other clinical studies in past 12 weeks. 8.Takes psychotropic medications that raise blood glucose (e.g. atypical antipsychotics) 9.Patients with ischemic heart disease, uncontrolled hypertension, myocardial infarction, cerebrovascular event, cardiac arrhythmia, Secondary hypothyroidism, Tertiary Hypo-thyroidism and active malignant disease were excluded from the study.

Design outcomes

Primary

Measure	Time frame
Improvement in HbA1CTimepoint: Day 0, Day 30, Day 60 and Day 90	—

Secondary

Measure	Time frame
FBS, PPBS, T3, T4, TSH lipid profile, BMI, HOMA-IR Index. BMI, waist hip ratio, and body weight, quality of life using WHOQOL-BREF score, Ayurvedic signs and symptoms of Prameha (~ Type 2 Diabetes Mellitus).Timepoint: Day 0, Day 30, Day 60 and Day 90	—

Countries

India

Contacts

Public ContactDr Sonam Chauhan

All India Institute of Ayurveda

mahtorajaram@yahoo.com8877033663

Outcome results